Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Antiviral Agents
/ administration & dosage
Benzamidines
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Drug Combinations
Guanidines
/ administration & dosage
Hemodiafiltration
/ methods
Humans
Hydroxychloroquine
/ administration & dosage
Japan
Lopinavir
/ administration & dosage
Male
Pandemics
Pneumonia, Viral
/ complications
Respiratory Insufficiency
/ complications
Ritonavir
/ administration & dosage
SARS-CoV-2
Treatment Outcome
COVID-19 Drug Treatment
COVID-19
Continuous hemodiafiltlation
Hydroxychloroquine
Nafamostat mesylate
SARS-CoV-2
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
09
04
2020
revised:
29
07
2020
accepted:
02
08
2020
pubmed:
8
9
2020
medline:
29
10
2020
entrez:
7
9
2020
Statut:
ppublish
Résumé
The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.
Identifiants
pubmed: 32893123
pii: S1341-321X(20)30271-3
doi: 10.1016/j.jiac.2020.08.001
pmc: PMC7409929
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antiviral Agents
0
Benzamidines
0
Drug Combinations
0
Guanidines
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Ritonavir
O3J8G9O825
nafamostat
Y25LQ0H97D
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1319-1323Informations de copyright
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflicts of interest in association with the present study.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Nat Rev Rheumatol. 2012 Sep;8(9):522-33
pubmed: 22801982
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Clin Infect Dis. 2020 Jul 16;:
pubmed: 32674126
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Int J Infect Dis. 2020 Jul;96:500-502
pubmed: 32470602
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Crit Care. 2020 Jul 3;24(1):392
pubmed: 32620147
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603